XNAS · Healthcare · Diagnostics & Research
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | 1.05 | 1.15 | +9.52% | $1.09B | ✅ Beat | -0.09% | +9.44% | +28.58% |
| 2026-02-05 | Q4 2025 | 1.25 | 1.35 | +8.00% | $1.16B | ✅ Beat | -9.44% | -14.35% | -6.73% |
| 2025-10-30 |
| Q3 2025 |
| 1.16 |
| 1.34 |
| +15.52% |
| $1.08B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 1.01 | 1.19 | +17.82% | $1.06B | ✅ Beat | — | — | — |
| 2025-02-06 | Q4 2024 | 0.92 | 0.95 | +3.26% | $1.10B | ✅ Beat | -9.56% | -17.12% | -29.99% |
| 2024-11-04 | Q3 2024 | 0.88 | 1.14 | +29.55% | $1.08B | ✅ Beat | +0.96% | -1.30% | -7.16% |
| 2024-08-06 | Q2 2024 | 0.90 | 0.36 | -60.00% | $1.11B | ❌ Miss | +4.07% | +2.89% | +11.52% |
| 2024-05-02 | Q1 2024 | 0.04 | 0.09 | +125.00% | $1.08B | ✅ Beat | -4.89% | -10.19% | -16.63% |
Showing last 8 quarters.